PIGINI, Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.446
EU - Europa 4.521
AS - Asia 3.848
SA - Sud America 453
Continente sconosciuto - Info sul continente non disponibili 239
AF - Africa 143
OC - Oceania 25
Totale 20.675
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.048
CN - Cina 1.742
SG - Singapore 1.058
RU - Federazione Russa 1.022
DE - Germania 931
IT - Italia 664
BR - Brasile 381
CA - Canada 327
UA - Ucraina 310
GB - Regno Unito 304
VN - Vietnam 284
SE - Svezia 277
FI - Finlandia 264
HK - Hong Kong 257
FR - Francia 251
PL - Polonia 202
TR - Turchia 118
ZA - Sudafrica 103
KR - Corea 98
IN - India 70
IE - Irlanda 69
BD - Bangladesh 56
CZ - Repubblica Ceca 51
BE - Belgio 45
MX - Messico 39
EU - Europa 35
JP - Giappone 34
NL - Olanda 29
AR - Argentina 28
IR - Iran 26
AU - Australia 23
ES - Italia 23
EC - Ecuador 17
LT - Lituania 17
IQ - Iraq 14
RO - Romania 13
PK - Pakistan 12
EG - Egitto 11
ID - Indonesia 11
CO - Colombia 10
JM - Giamaica 10
IL - Israele 8
MA - Marocco 8
PH - Filippine 7
RS - Serbia 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
CH - Svizzera 6
DZ - Algeria 6
NP - Nepal 6
JO - Giordania 5
KE - Kenya 5
SA - Arabia Saudita 5
TW - Taiwan 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BG - Bulgaria 4
CL - Cile 4
EE - Estonia 4
HU - Ungheria 4
NI - Nicaragua 4
PE - Perù 4
VE - Venezuela 4
AL - Albania 3
AZ - Azerbaigian 3
GR - Grecia 3
HN - Honduras 3
KH - Cambogia 3
MY - Malesia 3
NG - Nigeria 3
PA - Panama 3
PY - Paraguay 3
SN - Senegal 3
BY - Bielorussia 2
CR - Costa Rica 2
DK - Danimarca 2
GT - Guatemala 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
QA - Qatar 2
SV - El Salvador 2
TH - Thailandia 2
UZ - Uzbekistan 2
AD - Andorra 1
AM - Armenia 1
AW - Aruba 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
BZ - Belize 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
HR - Croazia 1
IS - Islanda 1
LB - Libano 1
LC - Santa Lucia 1
LK - Sri Lanka 1
Totale 20.466
Salva come PNG Salva come JPEG
Città #
Dallas 980
Ashburn 926
Woodbridge 774
Jacksonville 747
Chandler 606
Singapore 595
Fairfield 574
San Jose 521
Ann Arbor 503
Wilmington 387
Houston 381
Council Bluffs 354
Beijing 297
Boardman 287
Nanjing 258
Hong Kong 248
Seattle 236
Toronto 191
Cambridge 188
Los Angeles 181
New York 170
Dearborn 169
The Dalles 155
Düsseldorf 139
Kraków 123
Helsinki 119
San Mateo 117
Ho Chi Minh City 103
Columbus 99
Nanchang 98
Seoul 96
Johannesburg 95
Princeton 95
Lawrence 93
Tongling 93
Lauterbourg 90
Istanbul 87
Buffalo 82
Santa Clara 76
Munich 74
Warsaw 74
Ogden 71
Dublin 68
Lachine 67
Moscow 66
London 63
Shanghai 60
Shenyang 59
São Paulo 59
Camerino 57
Kunming 57
Orem 57
Hanoi 56
Tianjin 55
Guangzhou 51
Milan 46
Brussels 45
Chicago 44
Venezia 44
Turku 43
Changsha 41
Jiaxing 41
Brno 40
Phoenix 38
Hebei 37
Jinan 33
Washington 33
Hangzhou 32
Nürnberg 32
Chennai 31
San Diego 30
Denver 28
Tokyo 28
Philadelphia 27
Venice 26
Zhengzhou 26
Brooklyn 25
Falls Church 25
Poplar 25
Frankfurt am Main 21
Montreal 21
Boston 20
Wuhan 20
Atlanta 19
Orange 19
Redwood City 19
Da Nang 17
Manchester 17
Mexico City 17
Taizhou 17
Fuzhou 16
Amsterdam 15
Leawood 15
Ningbo 15
Stockholm 15
Verona 15
Monmouth Junction 14
Old Bridge 14
San Francisco 14
Hefei 13
Totale 13.500
Salva come PNG Salva come JPEG
Nome #
1,4-DIOXANE NUCLEUS AS A SUITABLE SCAFFOLD FOR NOVEL D2-LIKE RECEPTOR LIGANDS 647
1,4-Dioxane, a Suitable Scaffold for the Development of Novel M3 Muscarinic Receptor Antagonists 638
1,4-Dioxane ring as a promising template of novel 5-HT1A full agonists 579
1'-Benzyl-3,4-dihydrospiro[2H-1-benzothiopyran-2,4'-piperidine] (Spipethiane), a potent and highly selective sigma1 lingand 572
Antagonism/Agonism modulation to build novel antihypertensives selectively triggering i1-imidazoline receptor activation 349
The Versatile 2-Substituted Imidazoline Nucleus as a Structural Motif of Ligands Directed to the Serotonin 5-HT1A Receptor 340
31st Camerino-Cyprus-Noordwijkerhout Symposium - Receptor Chemistry Skyline 337
Hyperphagic effect of novel compounds with high affinity for imidazoline I2 binding sites 317
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 309
Combined Interactions with I1-, I2-Imidazoline Binding Sites and α2-Adrenoceptors To Manage Opioid Addiction 302
Novel ligands rationally designed for characterizing I2-imidazoline binding sites nature and functions 292
2-(2-Phenylcyclopropyl)imidazolines: Reversed Enantioselective Interaction at I1 and I2 Imidazoline Receptors 280
Investigation of allyphenyline efficacy in the treatment of alcohol withdrawal symptoms 266
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement. 258
Design, synthesis and muscarinic activity of deoxamuscarine-related derivatives 257
alpha(2)-Adrenoreceptors profile modulation. 2. Biphenyline analogues as tools for selective activation of the alpha2C-subtype 250
Biological profile and bioavailability of imidazoline compounds on morphine tolerance modulation 249
14th Camerino-Noordwijkerhout Symposium - Ongoing Progress in Receptor Chemistry 248
Binding of nicotine and homoazanicotine analogues at neuronal nicotinic acetylcholinergic (nACh) receptors 246
Deoxamuscaroneoxime Devatives as useful Muscarinic Aginist to Explore the Muscarinic Subsite: Demox, Amodulator of Orthosteric and Allosteric Site at Cardiac Muscarinic M2 Receptors. 240
Imidazoline binding sites (IBS) profile modulation: Key role of the bridge in determining I1-IBS or I2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues 237
Novel 1,4-dioxane derivatives as NMDA receptor channel blockers 234
Discovery of Highly Selective Imidazoline Receptor Ligands 232
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes 226
Structure−Activity Relationships in 1,4-Benzodioxan-Related Compounds. 11.1 Reversed Enantioselectivity of 1,4-Dioxane Derivatives in α1‑Adrenergic and 5‑HT1A Receptor Binding Sites Recognition 226
Structure-activity relationships in 1,4-benzodioxan-related compounds. Investigation on the role of the dehydrodioxane ring on alpha1-adrenoreceptor blocking activity 226
Novel Highly Potent and Selective σ1 Receptor Antagonists Related to Spipethiane 225
3-Phenyl analogues of 2-[[[2-(2,6-Dimethoxyphenoxyethyllamino]methyl]-1,4-benzodioxan (WB 4101) as highly selective alpha1-adrenoreceptor antagonists1 225
Synthesis and muscarinic properties of (1S*,3R*,5R*)-trimethyl(1-methyl-6-oxabicyclo[3.1.0]hex-3-yl)methyl ammonium iodide 220
31st Camerino-Cyprus-Noordwijkerhout Symposium - Receptor Chemistry Skyline 218
Muscarinic subtypes profile modulation within a series of new antagonists, bridged bicyclic derivatives of 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine 217
16th Camerino-Noordwijkerhout Symposium - An Overview of Receptor Chemistry 217
Alpha(2)-Adrenoreceptors Profile Modulation. 3. (R)-(+)-m-Nitrobiphenyline, a New Efficient and alpha(2C)-Subtype Selective Agonist. 216
Homoazanicotine: A structure-affinity study for nicotinic acetylcholine (nACh) receptor binding 216
Novel Imidazoline Compounds as Partial or Full Agonists of D2-Like Dopamine Receptors Inspired by I2-Imidazoline Binding Sites Ligand 2-BFI 216
Low doses of allyphenyline and cyclomethyline, effective against morphine dependence, elicit an antidepressant-like effect 216
Might Adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine? 215
Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation 211
28th Camerino-Cyprus-Noordwijkerhout Symposium - Trekking through Receptor Chemistry 211
Alpha(2)-adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole 208
Use of frozen sections for the pharmacological characterization of compounds active on neurotransmitter receptors 208
Enantioselective interactions to improve adrenergic α2C-agonism/α2A-antagonism 208
Novel Dopamine Receptor Ligands Bearing Imidazoline Nucleus. 207
Potent muscarinic antagonists bearing 1,4-dioxane scaffold 205
NOVEL BIVALENT LIGANDS OF XANOMELINE AND 77-LH-28-1 AS POTENTIAL M1 MUSCARINIC AGONISTS 205
Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity 203
Chain-lengthened and imidazoline analogues of nicotine 202
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 202
Muscarinic Thioligands with Cyclopentane Nucleus 199
“Pharmacological Characterization of Muscarinic Receptor Subtypes in Rabbit Isolated Tissue Preparations” 198
Age-related Changes in the Density of Muscarinic Cholinergic M1 and M2 Receptor Subtypes in Pyramidal Neurons or the rat Hippocampus 198
Allyphenyline analogues potentially useful in the management of chronic pain and opioid addiction. 197
Synthesis, Absolute Configuration, and Biological Profile of the Enantiomers of trans-[2-(2,6-Dimethoxypheoxy)ethyl] [(3-p-tolyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amine (Mephendioxan), a Potent Competitive alpha 1A-Adrenoreceptor Antagonist 196
Fruitful Adrenergic alpha(2C)-Agonism/alpha(2A)-Antagonism Combination to Prevent and Contrast Morphine Tolerance and Dependence 196
Structure-activity relationships in 1,4-benzodioxan-related compounds. 9.From 1,4-benzodioxan to 1,4-dioxane ring as a promising template of novel alpha(1D)-adrenoreceptor antagonists, 5-HT1A full agonists, and cytotoxic agents. 196
Ligand binding to I2 imidazoline receptor: the role of lipophilicity in quantitative structure-activity relationship models 196
alpha(2)-adrenoreceptors profile modulation. 4. From antagonist, to agonist behavior 195
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4 chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation 193
Synthesis and Structure-Activity Relationship Studies in a Series of 2-Substituted 1,3-Dioxolanes Modified at the Cationic Head. 192
Agonists and antagonists targeting the different alpha(2)-adrenoceptor subtypes 190
Pharmacophore development and 3D-QSAR study of I1 imidazoline binding site ligands 189
Rational design of novel I1-imidazoline receptor agonists 187
Dual Alpha2C/5HT1A Receptor Agonist Allyphenyline Induces Gastroprotection and Inhibits Fundic and Colonic Contractility 186
MORPHINE TOLERANCE MODULATION INDUCED BY alpha2-ADRENERGIC OR/AND I2 IMIDAZOLINE BINDING SITES LIGANDS 184
Effects of allyphenyline on chronic alcohol intoxication model 182
Rational design of new alpha(2)-adrenoreceptor agonists 182
Imidazoline receptors: Qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity 181
Might adrenergic α2C-agonist/α2A-antagonist become a novel therapeutic multitarget tool for morphine chronic treatment of pain? 180
Adrenoceptors as targets in drug discovery: Medicinal chemistry and therapeutical potential 177
Byciclic dioxolanes as potential antimuscarinic agents 176
From benzodioxane to 1,4-dioxane scaffold in the design of 5-HT1A serotoninergic full agonists from α1-adrenergic antagonists 175
Imidazoline nucleus as a biologically versatile scaffold 175
I1 imidazoline receptor-mediated effects on apoptotic processes in PC12 cells. 172
Hybrid molecules from xanomeline and 77-LH-28-1 as potential novel M1 muscarinic agonists 169
Structure- Activity Relationships in 1,4-Benzodioxan-related Compounds. 4. Effect of aryl and alkyl Substituents at Position 3 on α-adrenoreceptor blocking activity 168
Structure-activity relationship at alpha-adrenergic receptors within a series of imidazoline analogues of cirazoline 165
Alpha 1-adrenoreceptor antagonists bearing a quinazoline or a benzodioxane moiety 164
Structure-Activity Relationships in 1,4-Benzodioxan-Related Compounds. 6. Role of the Dioxane Unit on Selectivity for Alpha1-Adrenoreceptor Subtypes 156
Molecular determinants in the binding of novel 1,4-benzodioxan-related α1D-adrenergic receptor antagonists: a computational study 153
Structural motives of imidazoline molecules favouring the serotonin 5-HT1A receptor activation 153
Separation of alpha-adrenergic and imidazoline/guanidinium receptive sites (IGRS) activity in a series of imidazoline analogues of cirazoline 153
Binding of Tracizolines to the Imidazoline Receptor. Role of Lipophilicity in Quantitative Structure-Activity Relationship Models. 152
Novel muscarinic antagonists designed on the 1,4-dioxane scaffold 150
Enantiomers of 6,6-diphenyl-1,4-dioxane derivatives to highlight stereochemical requirements for selective alpha1D-AR and 5- HT1A receptor recognition 147
Structure-activity relationships in 1,4-benzodioxan-related compounds. 10. Novel alpha1-adrenoreceptor antagonists related to openphendioxan: synthesis, biological evaluation, and alpha1d computational study 147
Copresence of 1,4-dioxane and quinuclidine nuclei in the design of novel muscarinic antagonists 144
Might the observed alpha2A-adrenoreceptor agonism or antagonism of allyphenyline analogues be ascribed to different molecular conformations? 141
Structure- Activity Relationships in 1,4-Benzodioxan-related Compounds. 5. Effects of Modification of the side chain on alpha-adrenoreceptor blocking Activity 140
Synthesis and alpha-blocking activity of some analogues of idazoxan 133
Synergic stimulation of serotonin 5-HT1A receptor and α2-adrenoceptors for neuropathic pain relief: Preclinical effects of 2-substituted imidazoline derivatives 133
Novel α1-adrenoreceptor antagonists related to openphendioxan: biological evaluation and α1d computational study 131
Coupling of I-1 Imidazoline Receptors to the cAMP Pathway: Studies with a Highly Selective Ligand, Benazoline 130
Alpha2C-adrenoceptor modulators: a patent review 126
Totale 20.675
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.307
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.307
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022672 0 0 0 74 66 61 25 75 74 118 63 116
2022/20231.528 176 54 66 238 172 204 10 102 284 87 85 50
2023/2024967 156 61 66 28 41 85 34 15 100 37 23 321
2024/20253.009 118 78 250 136 74 156 377 719 246 187 203 465
2025/20265.147 289 353 1.083 667 524 387 692 282 246 248 207 169
2026/20271.314 245 141 447 481 0 0 0 0 0 0 0 0
Totale 20.675